Orchid Pharma
Vertically integrated pharmaceutical company producing APIs and formulations.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $16.6m | Post IPO Debt | |
| Total Funding | 000k | ||
| INR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 24 % | 19 % | 23 % | 13 % | 18 % | 48 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 14 % | 11 % | 15 % | 17 % | 16 % | 11 % | 15 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (26 %) | - | 7 % | 11 % | 11 % | 13 % | 11 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1 % | 1 % | 1 % | 1 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Orchid Pharma Limited is an integrated Indian pharmaceutical company established on July 1, 1992, by Kailasam Raghavendra Rao. Initially starting as an export-oriented unit for cephalosporin antibiotics, the company went public in 1995 and is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India.
The company's business model is vertically integrated, covering the entire pharmaceutical value chain from research and development to manufacturing and marketing. It develops and manufactures Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Orchid's core competency lies in Cephalosporin APIs, which are used in anti-bacterial and anti-inflammatory drugs. Its product portfolio is diverse, with a multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular (CVS), and nutraceuticals.
Orchid Pharma has a significant global presence, exporting to over 40 countries and maintaining alliances with international pharmaceutical majors. Historically, the company achieved milestones like being the first Indian company to receive US FDA approval for an India-manufactured API in 2005 and becoming the country's largest producer of cephalosporin in 1999. However, it faced challenges, leading to a Corporate Insolvency Resolution Process (CIRP). In March 2020, the Dhanuka Group acquired the company through its arm, Dhanuka Laboratories Limited. Under new management, the company has focused on a turnaround, becoming debt-free and charting growth through backward integration, including a significant investment in a new facility in Jammu under the Indian government's Production-Linked Incentive (PLI) scheme. In August 2025, Orchid received court approval in France to acquire the assets of Allecra Therapeutics.
Keywords: Active Pharmaceutical Ingredients, Finished Dosage Forms, Cephalosporin, anti-infectives, pharmaceutical manufacturing, drug discovery, global generics, Dhanuka Group, anti-inflammatory, cardiovascular drugs, nutraceuticals, export-oriented unit, USFDA compliant, vertically integrated, CIRP, production linked incentive, antimicrobial resistance, Enmetazobactam